Population-based efficacy modeling of omalizumab in patients with severe allergic asthma inadequately controlled with standard therapy

AAPS Journal

Volumn 15, Issue 2, 2013, Pages 559-570

  Zhu, Rui ^a   Zheng, Yanan ^a   Putnam, Wendy S ^a   Visich, Jennifer ^a   Eisner, Mark D ^a   Matthews, John G ^a   Rosen, Karin E ^a   D'Argenio, David Z ^b  

^a GENENTECH INC   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

asthma; FEV1; IGE; omalizumab; population modeling

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BIOLOGICAL MARKER; CORTICOSTEROID; FLUTICASONE; IMMUNOGLOBULIN E; LONG ACTING DRUG; NITRIC OXIDE; OMALIZUMAB; PLACEBO; SALMETEROL;

ADOLESCENT; ADULT; AGED; ALLERGIC ASTHMA; ARTICLE; CHILD; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; DRUG MEGADOSE; EXPIRED AIR; FEMALE; FORCED EXPIRATORY VOLUME; FRACTIONAL EXHALED NITRIC OXIDE; HEALTH STATUS; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PHARMACODYNAMICS; POPULATION RESEARCH; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RESPIRATORY TRACT INFLAMMATION; RESPIRATORY TRACT PARAMETERS; SCHOOL CHILD; STEADY STATE; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; BIOLOGICAL MARKERS; BREATH TESTS; CHILD; COMPUTER SIMULATION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; IMMUNOGLOBULIN E; LUNG; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MONTE CARLO METHOD; NITRIC OXIDE; PROSPECTIVE STUDIES; SPIROMETRY; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84877071832     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-013-9463-9     Document Type: Article

References (43)

1. Masoli M, Fabian D, Holt S, Beasley R. Global Initiative for Asthma (GINA) Program. The global burden of asthma: Executive summary of the GINA Dissemination Committee report. Allergy. 2004;59:469-78. doi: 10.1111/j.1398-9995.2004.00526.x.
2. Beasley R. The burden of asthma with specific reference to the United States. J Allergy Clin Immunol. 2002;109(Suppl):482-9. doi: 10.1067/mai.2002. 122716.
3. Global Initiative for Asthma. Global strategy for asthma management and prevention (updated 2010). http://www.ginasthma.org/pdf/GINA-Report-2010.pdf (2010). Accessed 17 Aug 2012.
4. Fendrick AM, Baldwin JL. Allergen-induced inflammation and the role of immunologlobulin E (IgE). Am J Ther. 2001;8:291-7.
5. Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med. 1989;320:271-7. doi: 10.1056/NEJM198902023200502.
6. Holt PG, Macaubas C, Stumbles PA, Sly PD. The role of allergy in the development of asthma. Nature. 1999;402(Suppl):B12-7.
7. Novak N, Bieber T. Allergic and nonallergic forms of atopic diseases. J Allergy Clin Immunol. 2003;112:252-62. doi: 10.1067/mai.2003.1595.
8. Prussin C, Metcalfe DD. 4. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol. 2003;111(Suppl):486-94. doi: 10.1067/mai.2003.120.
9. Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol. 2005;115:459-65. doi: 10.1016/j.jaci.2004.11.053.
10. Vollmer WM, Buist AS, Johnson LR, McCamant LE, Halonen M. Relationship between serum IgE and cross-sectional and longitudinal FEV1 in two cohort studies. Chest. 1986;90:416-23. doi: 10.1378/chest.90.3.416.
11. Sherrill DL, Lebowitz MD, Halonen M, Barbee RA, Burrow B. Longitudinal evaluation of the association between pulmonary function and total serum IgE. Am J Respir Crit Care Med. 1995;152:98-102.
12. Shadick NA, Sparrow D, O'Connor GT, DeMolles D, Weiss ST. Relationship of serum IgE concentration to level and rate of decline of pulmonary function: The normative aging study. Thorax. 1996;51:787-92.
13. Zeiger RS, Heller S. The development and prediction of atopy in high-risk children: Follow-up at age seven years in a prospective randomized study of combined maternal and infant food allergen avoidance. J Allergy Clin Immunol. 1995;95:1179-90. doi: 10.1016/S0091-6749(95)70074-9.
14. Lowe PJ, Tannenbaum S, Gautier A, Jimenez P. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br J Clin Pharmacol. 2009;68:61-76. doi: 10.1111/j.1365-2125.2009.03401.x.
15. Ahmad Al Obaidi AH, Mohamed AI Samarai AG, Yahya Al Samarai AK, Al Janabi JM. The predictive value of IgE as biomarker in asthma. J Asthma. 2008;45:654-63. doi: 10.1080/02770900802126958.
16. Piacentini GL, Bodini A, Costella S, Vicentini L, Mazzi P, Sperandio S, et al. Exhaled nitric oxide and sputum eosinophil markers of inflammation in asthmatic children. Eur Respir J. 1999;13:1386-90.
17. Warke TJ, Fitch PS, Brown V, Taylor R, Lyons JDM, Ennis M, et al. Exhaled nitric oxide correlates with airway eosinophils in childhood asthma. Thorax. 2002;57:383-7. doi: 10.1136/thorax.57.5.383.
18. Payne DN, Adcock IM, Wilson NM, Oates T, Scallan M, Bush A. Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in children with difficult asthma, after treatment with oral prednisolone. Am J Respir Crit Care Med. 2001;164:1376-81.
19. Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, et al. An official ATS clinical practice guideline: Interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184:602-15. doi: 10.1164/rccm.9120-11ST.
20. Sacco O, Sale R, Silvestri M, Serpero L, Sabatini F, Raynal ME, et al. Total and allergen-specific IgE levels in serum reflect blood eosinophilia and fractional exhaled nitric oxide concentrations but not pulmonary functions in allergic asthmatic children sensitized to house dust mites. Pediatr Allergy Immunol. 2003;14:475-81. doi: 10.1046/j.0905-6157.2003.00092.x.
21. Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, et al. Omalizumab in severe allergic asthma in inadequately controlled with standard therapy: A randomized trial. Ann Intern Med. 2011;154:573-82.
22. Hochhaus G, Brookman L, Fox H, Johnson C, Matthews J, Ren S, et al. Pharmacodynamics of omalizumab: Implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin. 2003;19:491-8. doi: 10.1185/030079903125002171.
23. Adelroth E, Rak S, Haahtela T, Aasand G, Rosenhall L, Zetterstorm O, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2000;106:253-9. doi: 10.1067/mai.2000.108310.
24. Hayashi N, Tsukamoto Y, Sallas WM, Lowe PJ. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol. 2007;63:548-61. doi: 10.1111/j.1365-2125.2006.02803.x.
25. Standardization of spirometry, 1994 update. American Thoracic Society. Am J Respir Crit Care Med. 1995;152:1107-36.
26. Solèr M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18:254-61.
27. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108:184-90. doi: 10.1067/mai.2001.117880.
28. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis. 1981;123:659-64.
29. Polgar G, Promadhat V. Pulmonary function testing in children: Techniques and standards. Philadelphia: W.B. Saunders; 1971. p. 170-80.
30. Wang X, Shang D, Ribbing J, Ren Y, Deng C, Zhou T, et al. Placebo effect model in asthma clinical studies: Longitudinal meta-analysis of forced expiratory volume in 1 second. Eur J Clin Pharmacol. 2012;68:1157-66. doi: 10.1007/s00228-012-1245-2.
31. Krzyanski W, Jusko WJ. Integrated functions for four basic models of indirect pharmacodynamics response. J Pharm Sci. 1998;87:67-72.
32. Schumitzky A. EM algorithms and two stage methods in pharmacokinetic population analysis. In: D'Argenio DZ, editor. Advanced methods of pharmacokinetic and pharmacodynamic systems analysis, vol. 2. New York: Plenum; 1995. p. 140-60.
33. Walker S. An EM, algorithm for nonlinear random effects models. Biometrics. 1996;52:934-44.
34. Bauer RJ, Guzy S. Monte Carlo parameter expectation maximization (MC-PEM) method for analyzing population pharmacokinetic/pharmacodynamic data. In: D'Argenio DZ, editor. Advanced methods of pharmacokinetic and pharmacodynamic systems analysis, vol. 3. Massachusetts: Kluwer Academic; 2004. p. 155-63.
35. D'Argenio DZ, Schumitzky A, Wang X. ADAPT 5 user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Los Angeles: Biomedical Simulations Resource; 2009.
36. Holford N. The visual predictive check - superiority to standard diagnostic (Rorschach) plots. Abstract 738, p. 14. http://www.page-meeting.org/? abstract=738 (2005). Accessed 25 Oct 2012.
37. Slavin RG, Ferioli C, Tannenbaum SJ, Martin C, Blogg M, Lowe PJ. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. J Allergy Clin Immunol. 2009;123:107.e3-13.e3. doi: 10.1016/j.jaci.2008.09.050.
38. Samara E, Cao G, Locke C, Granneman GR, Dean R, Killian A. Population analysis of the pharmacokinetics and pharmacodynamics of seratrodast in patients with mild to moderate asthma. Clin Pharmacol Ther. 1997;62:426-35. doi: 10.1016/S0009-9236(97)90121-1.
39. Zhou H, Hu C, Zhu Y, Lu M, Liao S, Yeilding N, et al. Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2010;50:257-67. doi: 10.1177/ 0091270009343695.
40. Hu C, Xu Z, Zhang Y, Rahman MU, Davis HM, Zhou H. Population approach for exposure-response modeling of golimumab in patient with rheumatoid arthritis. J Clin Pharmacol. 2011;51:639-48. doi: 10.1177/0091270010372520.
41. Johansson SGO, Nopp A, Öman H, Ankerst J, Cardell LO, Grönneberg R, et al. The size of the disease relevant IgE antibody fraction in relation to 'total-IgE' predicts the efficacy of anti-IgE (Xolair) treatment. Allergy. 2009;64:1472-7. doi: 10.1111/j.1398-9995.2009.02051.x.
42. MacGlashan Jr DW, Peters SP, Warner J, Lichtenstein LM. Characteristics of human basophil sulfidopeptide leukotriene release: Releasability defined as the ability of the basophil to respond to dimeric cross-links. J Immunol. 1986;136:2231-9.
43. MacGlashan Jr DW. Releasability of human basophils: Cellular sensitivity and maximal histamine release are independent variables. J Allergy Clin Immunol. 1993;91:605-15.